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MicroRnA molecules as predictive 
biomarkers of adaptive responses 
to strength training and physical 
inactivity in haemodialysis patients
ivana Spakova1,9, Aurel Zelko2,3,9*, Miroslava Rabajdova1,9, Peter Kolarcik2,4,7, 
Jaroslav Rosenberger2,4,5,6, Martina Zavacka8, Maria Marekova1, 
Andrea Madarasova Geckova2,4,7,9, Jitse P. van Dijk2,4,7,9 & Sijmen A. Reijneveld7,9
The miRNA-206 and miRNA-23a play an important role in muscle tissue hypertrophy, regeneration 
and atrophy. Both of these miRNAs have been highlighted as promising adaptation predictors; 
however, the available evidence on associations is inconclusive. Therefore, our aim was to assess the 
expression levels of these two miRnAs as predictors of change in muscle function during strength 
training and physical inactivity among dialysed patients. For this purpose, 46 haemodialysis patients 
were monitored for 12-weeks of either intradialytic strength training (EXG, n = 20) or physical 
inactivity during dialysis (CON, n = 26). In both groups of patients, we assessed the baseline expression 
levels of miRNA-23a and miRNA-206 and the isometric force generated during hip flexion (HF) 
contraction before and after the 12-week period. Among the EXG group, the expression of miRNA-
206 predicted the change in HF  (R2 = 0.63, p = 0.0005) much more strongly than the expression of 
miRNA-23a  (R2 = 0.21, p = 0.027). Interestingly, baseline miRNA-23a  (R2 = 0.30, p = 0.006) predicted the 
change in HF much more than miRNA-206 (p = ns) among the CON group. Our study indicates that the 
baseline expression of miRNA-206 could predict the response to strength training, while miRNA-23a 
could serve as a potential predictive marker of functional changes during physical inactivity in dialysis 
patients.
Patients In haemodialysis (CKD5-HD) patients, muscle functioning is strongly associated with  hospitalizations1, 
mortality  risks1,2, functional  independence3, mobility and quality of  life4,5. Chronic haemodialysis therapy is 
accompanied by a deterioration in muscle functions and  weakness6,7. To counteract these health risks various 
interventional approaches have been proposed and strength training is considered to be an effective instrument 
for maintaining favourable muscle function in CKD5-HD  patients8. Besides clinical efficiency in the prevention 
of functional loss, large individual differences in the physiological response to strength training and inactivity 
have been reported among CKD5-HD  patients9,10.
Micro ribonucleic acids (miRNA) are synthesized, selectively packaged and actively secreted into circula-
tion by a variety of cell  types11. In circulation, miRNAs may be delivered to the recipient cells where they can 
regulate the translational activity of target  genes12. Since their discovery, several miRNAs have been identified as 
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biomarkers of normal  development13,14 and pathophysiology of the muscular  system15–17. More recent research 
has been conducted in the field of miRNAs functions in physiological adaptation during exercise  interventions18, 
and miRNA-206 has been found to play an important role in  myogenesis19, skeletal muscle  regeneration20 and 
regulation of myostatin mRNA  activity21,22. These physiological processes are necessary for the adaptation of 
muscle tissue after strength training. On the other hand, miRNA-23a interacts with the Muscle RING finger 
protein 1 (MuRF1) and the Muscle specific ligases atrophy F-box (MAFbx) signalling pathways, which closely 
regulate protein breakdown in skeletal muscle  tissue23. Additionally, an miRNA-23a cluster affects proteolysis 
and mitochondrial integrity activity of inflammatory  cytokines24,25, and miRNA-23a/miRNA-27a clusters have 
been considered for therapeutic use as an exercise mimetic for muscle wasting during critical and chronic disease 
 conditions26,27.
Both miRNAs are physiologically active in muscle cells. They have the effect of the family member 2 and 3 
(SMAD2/3) signalling pathways in cells (Fig. 1) through the promotion and inhibition of the Phosphatidylino-
sitol-3-kinase/Phosphorylated serine-threonine kinase pathway (PI3K/Akt/mTOR) and Calcineurin.
The expression level of miRNA-206 has been correlated negatively with peripheral insulin  sensitivity28 and 
reduced miRNA-206 levels increase insulin-like growth factor-1 (IGF-1) mRNA  levels29 in the PI3K/Akt/mTOR 
Figure 1.  Summary of interactions and actions of miRNA-206 and miRNA-23a in the PI3K/Akt/mTOR, 
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signalling pathway. Myoblast determination proteins (MyoD) and the paired-box transcription factor (Pax) in the 
SMAD 2/3 signalling pathway are essential for muscle satellite cell proliferation and differentiation. Enhanced 
or reduced MyoD activity affects the expression of miRNA-206, and its altered expression causes resistance or 
acceleration of the apoptosis processes of myoblasts. The elevated expression of miRNA-206 suppresses the 
expression of Pax7, which restricts muscle satellite cells proliferation and promotes their  differentiation20,30,31. A 
decrease in the expression of miRNA-206 increases the activation of Pax3, which suppresses the differentiation 
of muscle satellite  cells32,33.
Activation of the Calcineurin (Cn) and the Nuclear factor of activated T cells (NFAT) signalling pathways 
increases miRNA-23a  expression34–36. MuRF1 and MAFbx are muscle-specific ubiquitin ligases downstream 
from the Calcineurin signalling pathway and play critical roles during protein ubiquitination and muscle tissue 
 atrophy37. MuRF1 and MAFbx are over-expressed during the activation of muscle atrophy, while the inhibition 
of MuRF1 and MAFbx attenuate atrophy  processes38,39. Increased expression of miRNA-23a is able to inhibit 
the translational activation of MuRF1 and MAFbx and thereby suppress atrophy processes in muscle  cells32. The 
increased concentration of miRNA-23a has been associated with down-regulation of SMAD2/3, with reduced 
concentrations of Phosphatase and tensin homolog (PTEN) and with the elevation of Akt  concentrations40. 
Therefore, we hypothesized that the baseline expression levels of Homo sapiens-miRNA-206 and hsa-miRNA-23a 
may strongly predict the adaptation to strength training and physical inactivity in CKD5-HD patients.
Evidence is very limited on the predictive relationship between resting, pre-interventional, Homo sapiens 
(hsa-)miRNAs and the adaptive response to strength training or physical inactivity. Margolis et al. investigated 
and compared the predictive association between hsa-miRNAs and exercise-induced adaptations following acute 
strength training among young and elderly healthy  subjects41. They found that dysregulation of hsa-miRNAs in 
the elderly served as predictive markers in age-associated declines in skeletal muscle mass, increased fat mass, 
and altered functional adaptability. However, only hsa-miRNA-206 was included in these predictive analyses. 
Therefore, in our study, we investigated the degree to which baseline levels of hsa-miRNA-206 and hsa-miRNA-
23a modified adaptive response to strength training and to physical inactivity in CKD5-HD patients.
Results
Patient flow. For the present investigation, data were analysed on 20 experimental patients and 26 control 
patients, who completed all the assessments of outcomes and were identified as physically inactive in pre-inter-
vention assessments.
Patients’ baseline characteristics. At baseline, the mean age of patients in the study was 66.2 ± 9.4. 
Among the patients included for analysis, 54% were male and the BMI was 26.0 ± 5.8 kg/m2 (Table 1). Baseline 
relative expression levels of the studied hsa-miRNAs were comparable between the EXG and CON groups.
Adaptive response during strength training intervention and physical inactivity. During the 
12-week strength training intervention in EXG patients, the maximal force during isometric HF increased 
by 15.9 N (SD 36.7; pre: 107.6 N, post: 123.5 N; + 14.8%). In CON patients the 12-weeks of physical inactiv-
ity resulted in an increase of the maximal isometric force during HF by 3.0  N (SD 26.9; pre: 96.3  N, post: 
99.3 N; + 3.1%). The relative force during isometric HF increased in the EXG group by 18.4 N/kg (SD 48.8; pre: 
139.1 N/kg, post: 157.5 N/kg; + 13.2%) and decreased in the CON group by 1.5 N/kg (SD 40.3, pre: 141.4 N/kg; 
post: 139.8 N/kg; − 1.1%).
Table 1.  Patients’ baseline characteristics and test of differences in these characteristics between the EXG 
and CON groups. Data are presented as mean ± standard deviation, hsa-miRNA relative expression data are 
presented as mean log10 (log10) of the respective miRNA ± standard deviation, p values determined by the 
unpaired Student´s t-test. iPTH, intact parathyroid hormone; EXG, experimental group; CON, control group. 
Differences between groups significant at p < 0.05 are marked by *. Differences between groups significant at 
p < 0.01 are marked by †.
Variable EXG (n = 20) CON (n = 26) p value
Age 63.9(9.9) 67.9 (8.9) 0.161
Gender (male/female) 11/9 14/12 0.938
Body mass index (kg/m2) 28.2 (6.5) 24.3 (4.6) 0.029*
Dialysis adequacy (Kt/V) 1.6 (0.4) 2.0 (0.3) 0.001†
Over-hydration index (%) 12.3 (6.2) 12.2 (6.9) 0.964
C-reactive protein (mg/l) 8.3 (10.7) 13.3 (14.4) 0.190
iPTH (pg/ml) 400.8 (375.3) 392.4 (460.4) 0.941
Albumin (g/l) 39.3 (3.0) 36.9 (4.4) 0.042*
Phosphates (mml/l) 1.6 (0.5) 1.5 (0.5) 0.396
Calcium (mmol/l) 2.1 (0.2) 2.3 (0.1) 0.001†
Hip flexion (N/kg) 107.6 (53.3) 96.3 (28.5) 0.397
hsa-miRNA-206 (log10) 42.7 (33.4) 17.5 (12.0) 0.013*
hsa-miR-23a (log10) 6557.2 (5139.0) 2132.8 (3944.0) 0.004†
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Do hsa‑miRNAs modify changes in muscle function in all study subjects? Regardless of the patient’s allocation, 
the baseline expression levels of hsa-miRNA-206 and hsa-miRNA-23a modified a change of relative force during 
isometric HF contraction. They accounted for 31.2% of its variance (p = 0.003). Assessing the hsa-miRNAs sepa-
rately, the baseline expression level of hsa-miRNA-206 explained 21.0% (p = 0.006) and the baseline expression 
level of hsa-miR-23a explained 12.5% (p = 0.020) of the variance in the change of relative force during isometric 
HF contraction (Fig. 2). Looking at the direction of associations with the change in patient’s muscle strength, we 
see that baseline expression of hsa-miRNA-206 was associated with an increase in isometric HF force and the 
baseline expression of hsa-miRNA-23a with a decrease in it.
Do hsa‑miRNAs modify changes in muscle function during strength training? The baseline expression level of 
hsa-miRNA-206  (R2 = 0.63; p = 0.0005; Fig. 3a) modified the adaptive response during the strength training more 
strongly than the baseline expression level of hsa-miRNA-23a  (R2 = 0.21; p = 0.027; Fig. 3a). Compared with data 
analysis in all subjects, the experimental group showed a stronger positive association between the baseline 
expression level of hsa-miRNA-206 and the change in relative force during isometric HF contraction, while the 
negative associations with the expression level of hsa-miRNA-23a remained moderate.
Do hsa‑miRNAs modify changes in muscle function during physical inactivity? The baseline expression level of 
hsa-miRNA-23a explained 29.5% of the variance in the change of relative force during isometric HF contraction 
(p = 0.006; Fig. 3b), while the baseline expression level of hsa-miRNA-206 showed no predictive association with 
the change in muscle functions  (R2 = 0.00; p = 0.986; Fig. 3b). Comparing the control group with all subjects, the 
association between the baseline expression level of hsa-miRNA-206 and the relative change in HF contraction 
force disappeared, while the negative associations with the expression level of hsa-miRNA-23a remained moder-
ate.
Discussion
We performed a quasi-experimental study to access the relationship between the expression level of two hsa-
miRNAs and functional adaptation during a period of physical activity and inactivity in CKD5-HD. We found 
that the baseline expression levels of hsa-miRNA-206 and hsa-miRNA-23a modifies changes in relative force 
during isometric HF contractions due to chronic resistance training and due to inactivity.
After the strength training intervention, the relative HF force of EXG patients increased considerably, by 
18.4 N/kg. We found that these improvements in muscle function were strongly predicted by the baseline expres-
sion level of hsa-miRNA-206 among CKD5-HD patients. Previous research has shown that the hsa-miRNA-206 
expression level predicts adaptation to strength training. That study compared the adaptability between young 
and elderly participants and reported that lower physiological responses to training and reduced anabolic sig-
nalling activity were accompanied by a lower baseline expression profile of hsa-miRNA-20641. This similarity 
with our results shows the independent role of hsa-miRNA-206 in physiological adaptation following physical 
activity intervention. The relationship between the hsa-miRNA-206 expression profile and the effects of physical 
activity may also be explained by in vitro studies and studies on non-human muscle  cells24. In both models, the 
higher miRNA-206 expression levels were accompanied by lower insulin sensitivity and by lower IGF-1 mRNA 
 levels28,29. Regular physical activity may improve insulin sensitivity and increase the expression of IGF-1 and 
thus make these patients much more adaptable to exercise interventions through higher activation of the PI3K/
Akt/mTOR signalling pathway. Margolis et al.41 also observed a close physiological interaction between hsa-
miRNA-206 and Akt activity. Moreover, the higher expression of hsa-miRNA-206 could inhibit Pax-7, which is 
known as a down-regulator of satellite cells proliferation in muscle  cells30,31. The higher functional adaptation 
Figure 2.  Regression analysis scatter plot of the relationship between the baseline expression level of hsa-
miRNA-23a and hsa-miRNA-206 and the change in relative HF contraction force in all subjects.
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in patients with higher hsa-miRNA-206 may be explained by higher satellite cell proliferation activity via the 
TGF-β/SMAD2-3/MyoD signalling pathway. These physiological pathways indeed seem to be able to lead to 
modification of the responses to exercise.
We also found that after the period of physical inactivity, the relative HF force of CON patients slightly 
decreased, by 1.5 N/kg. We found that the deterioration in muscle function observed after the period of physi-
cal inactivity was predicted by the baseline expression level of hsa-miRNA-23a among CKD5-HD patients, i.e. 
that this modified the physiological response to inactivity. This may be explained by the modifications in gene 
expression and signalling pathways activity that were previously observed in patients during physical inactivity. 
For example, Duan et al.57 found that hsa-miRNA-23a was one of the differentially expressed genes associated 
with the loss of quadriceps muscle force during disease in patients during with an acute exacerbation of chronic 
obstructive pulmonary disease. A possible explanation for this may be that the higher expression of hsa-miRNA-
23a down-regulated the activation of MuRF1 and MAFbx and decreased atrophy processes in muscle cells via the 
Calcineurin/NFAT signalling  pathway32. It has been suggested that the higher expression of hsa-miRNA-23a may 
be positively associated with muscle functions. The observed negative associations between hsa-miRNA-23a and 
muscle function in our study are surprising and may be explained by the complementary effects of hsa-miRNA-
23a in the PI3K/Akt/mTOR and the Myostatin/TGF-β/SMAD2-3/MyoD signalling pathways. In both pathways, 
higher expression levels of hsa-miRNA-23a down-regulates the anabolic and regenerative physiological effects 
via PTEN and SMAD2/3p. The decreased hsa-miRNA-23a expression in inactive patients may up-regulate both 
signalling pathways and help muscle cells to maintain sufficient anabolic signalling activity for the preservation 
of muscle cell volume and functions during physical inactivity.
This is the first study which examines associations between the expression profile of hsa-miRNA-206 and hsa-
miRNA-23a and changes in muscle function during exercise intervention and inactivity in dialysed patients. We 
found that baseline expression of hsa-miRNA-206 is a strong predictor of functional adaptation during strength 
training and that hsa-miRNA-23a is a moderate predictor of functional changes during physical inactivity.
Figure 3.  (a) Regression analysis scatter plot of the relationship between the baseline expression level of hsa-
miRNA-23a and hsa-miRNA-206 and the change in relative HF force in the EXG group. (b) Regression analysis 
scatter plot of the relationship between the baseline expression level of hsa-miRNA-23a and hsa-miRNA-206 
and the change in relative HF force in the CON group.
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To the best of our knowledge, this study is the first to identify the modifying effects of the baseline expression 
levels of hsa-miRNA-206 and hsa-miRNA-23a on the change of lower extremity muscle strength during physical 
activity and inactivity among CKD5-HD patients. The sample size and closely monitored interventional condi-
tions are major main strengths of this study. Given that our findings are based on a limited number of miRNAs 
and no encoded proteins analysis, the results from our data analyses should be treated with considerable caution.
Our findings of associations between muscle function changes and hsa-miRNA-206 during strength training 
and hsa-miRNA-23 during physical inactivity could be used in the development of molecular biology instru-
ments to effectively slow down and prevent the muscle function deterioration that frequently accompanied 
acute life-threatening and chronic disease conditions. Our findings are also important for the management and 
implementation of an intradialytic exercise intervention on dialysed patients. In patients with a higher baseline 
expression of hsa-miRNA-206, the application of strength training will likely yield favourable physiological effects 
and should be strongly recommended. In patients with low baseline expression of hsa-miRNA-206, the train-
ing intervention could be modified (length of intervention, type of exercise, dosage of exercise, etc.) to achieve 
similar adaptation effects compared to the high-expression patients.
Methods
Study design. We embedded the assessment of the hsa-miRNA predictive value in a quasi-experimental, 
two-group, pre-post comparative study at three dialysis centres in Slovakia (Fresenius Medical Care Dialysis 
Services in Kosice, Logman East in Kosice and Fresenius Medical Care Dialysis Services in Banska Bystrica). 
The study design and protocol were reviewed and approved by the Ethics Committee of Pavol Jozef Safarik Uni-
versity in Kosice (approval no. 14N/2017) and registered at ClinicalTrials.gov (ID:NCT03511924). All methods, 
assessments and data acquisitions were conducted according to the relevant ethics guidelines and regulations, 
based on the Declaration of Helsinki (1975, as revised in 2013) and followed the study  protocol42.
Participants. We included patients with end-stage renal disease who were over 30 years of age and had been 
receiving treatment by maintenance dialysis therapy for at least the last three months. Potential participants were 
screened and selected through their nephrologists. Individuals were excluded if they had lower extremity ampu-
tation, severe dementia or retardation, an acute intercurrent disease or if their probability of one-year mortality 
was higher than 25% according to the Charlson Comorbidity  Index43. All assessments and training sessions were 
done at the three cooperating dialysis centres. All 198 CKD5-HD patients were screened and selected according 
to the inclusion and exclusion criteria at these centres, yielding 126 eligible patients (63.6% eligible patients). 
These received oral and written information about the possibility of participating in the study, leading to 90 
patients signing a written informed consent (71.4% response rate) prior to the study.
Patient allocation. Patients attending dialysis therapy at both sites in Kosice were allocated to the experi-
mental group (EXG, n = 57), while patients from the Banska Bystrica dialysis centre were allocated to the control 
group (CON, n = 33). After the allocation procedure, the investigatory team members and participating patients 
were informed about the group assignment  structure58.
Intervention. The intervention has been described in details in study protocol  publication42. Patients allo-
cated to the EXG participated in a 12-week intradialytic resistance training (IRT) programme, which they per-
formed under the supervision of training assistants, three times per week during the dialysis therapy. IRT sessions 
lasted 40 min and were composed of 3-min of warming-up, 30-min of conditioning and 7-min of cooling-down 
and stretching. To perform effective exercises in a supine position during dialysis, we used external pressure 
generated by elastic bands and over-balls (TheraBand, OH, USA). These external loading resources (bands and 
balls) were fixed on the construction of the dialysis bed and during exercises, patients pulled or pushed against 
them. The applied intensity of IRT was medium corresponding with 11–14 out of 20 at the rate of The Borg Scale 
of Perceived  Exertion44. The progress of the IRT programme strongly depended on the patient’s physical abilities 
and clinical condition. During the first two weeks of the IRT programme, patients performed per session three 
sets (12–15 repetitions each) of three different exercises for the lower extremity muscles (I. unilateral push and 
pull of the over-ball against a leg board, II. bilateral knee squeeze of the over-ball, and III. unilateral straight leg 
raise against the band pressure). Once a patient was capable of safely completing the planned programme for 
the session concerned, the numbers of repetitions in the next session increased with three repetitions for each 
exercise. If a patient reached the maximum number of repetitions per exercise (18 repetitions) during a session, 
then for the next session the number of sets was increased by one set, and the initial number of repetitions per 
exercise became 12. When the patient was able to perform five sets with 18 repetitions for each exercise, we 
made the IRT harder by applying a stiffer elastic band or an over-ball with higher hardness. If a patient failed to 
complete the entire training session, or had obvious difficulties, the IRT was facilitated by lowering the number 
of repetitions per set, or of sets, or by the application of softer elastic bands and over-balls42. This methodology of 
training progressivity enabled us to maintain the patient’s safety during IRT and ensured the intensity of training 
to be between “moderate” and “hard”.
Control conditions. Patients allocated to the CON group received their standard nephrology care and 
remained physically inactive during dialysis. Through the 12-week control period, all CON patients maintained 
their standard treatment regimen and their customary dietary and physical activity patterns. The CON patients 
were informed about the clinical benefits and effects of regular physical activity in CKD5-HD patients, and dur-
ing the control period they were received increased attention from the research team  members58.
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Measures. The primary outcome of the study was the relative change in maximal isometric force generated 
during hip flexion (HF) contraction. The maximal isometric forces (1RM) generated during HF of patients were 
assessed by a hand-held dynamometer (Universal digital force gauge HF 500, SAUTER GmbH, Balingen, Ger-
many). During the assessments, patients were in a supine position and held the dominant leg in a straightened 
position, while the dynamometer was placed proximally to the ankle, on the anterior surface of the lower leg. The 
patients were instructed to perform a maximal isometric contraction and hold it for 5 s. The tests were repeated 
with 30-s rest intervals, and the higher values of two consecutive tests were used for the analysis as absolute val-
ues of 1RM (measure unit: Newton; N). The absolute values of 1RM were subsequently divided by the subject’s 
body weight to determine relative 1RM forces (Newton per kilogram; N/kg). Changes in the relative 1RM forces 
during HF were calculated for experimental and control conditions as the post-intervention measure minus the 
baseline measure.
The potential modifiers of the study included the resting, pre-interventional expression profile of hsa-
miRNA-206 and hsa-miRNA-23a. Immediately after venous blood collection by a closed sampling system at 
the dialysis centres, blood was distributed into the dipotassium ethylenediaminetetraacetic acid anti-coagulation 
containing tubes and into tubes with a pro-coagulation solution. Samples were centrifuged at 3500×g at 4 °C for 
3 min and the extracted samples containing separated plasma and serum were immediately stored at − 80 °C. 
All plasma samples were processed and analysed in a single laboratory batch 12 months after the first sample 
collection. During processing in the lab, samples were defrosted on ice and then 220 ml aliquots from the sam-
ples were centrifuged at 4 °C for 10 min (1000×g) to remove of potential residues. In the next step, total RNA 
including target miRNAs was isolated from 200 ml of plasma with the miRNeasy Serum/Plasma Kit (Qiagen, 
Hilden, Germany). The miRNA isolation efficiency was measured using the Qubit microRNA assay kit (Thermo 
Fisher Scientific, MA, USA).
Isolated RNA samples were processed for reverse transcription of hsa-miRNA-23a and hsa-miRNA-206 into 
cDNA using the TaqMan reverse transcription reagents kit (Thermo Fisher Scientific, MA, USA) and miRNA-
specific primers (Thermo Fisher Scientific, MA, USA). The Reverse PCR was performed in a thermocycler in a 
three steps reaction as follows: Primer Extension 16 °C for 30 min, cDNA synthesis 42 °C for 30 min, Reaction 
Termination 85 °C for 5 min, and cooling to 4 °C. The concentrations of the target miRNAs were analysed by 
using quantitative real-time PCR by application of TaqMan Master Mix II not containing uracil-N-glycoslyase 
and specific TaqMan MicroRNA Assays on a Rotor-Gene Quantitative-Polymerase Chain Reaction Thermocycler 
(Qiagen, Hilden, Germany). The RT-PCR analyser was set in four steps as follows: Hold 1 (50 °C, 2 min), Hold 
2 (95 °C, 10 min), 40 Cycles (95 °C, 15 s, 60 °C, 1 min), and Hold 3 (40 °C, 10 min).The analyses of the hsa-
miRNAs concentrations were performed twice for each sample, with the acceptable intra-assay variation set at 
4%. Final quantification of individual hsa-miRNAs levels was done using the Rotor-Gene Q software (Qiagen, 
Hilden, Germany). The comparative threshold cycle (CT) method, with “housekeeping” references RNU44, U6, 
ΔCT−40 and the average ΔCT of analysed samples as the endogenous control were used for individual hsa-miRNAs 
 quantification46–47. After this normalization, the delta threshold cycle (ΔCT) values were used to determine the 
delta delta threshold cycle (ΔΔCT) and obtain the relative amount of the miRNA to be determined using the 
formula for relative quantification (target gene 1) = 2−ΔΔCT(target gene 1)48,49.
Background variables regarded (a) patient’s age and gender, (b) body composition parameters (body weight 
and body height) and (c) nephrological clinical data containing over-hydration status, dialysis adequacy (Kt/V) 
and concentrations of C-reactive protein, parathyroid hormone, albumin, phosphates and calcium. These were 
extracted from patients’ electronic medical record right before the start of the intervention. The body mass index 
was calculated as body weight in kilograms divided by the square of the body height in metres (BMI, kg/m2). 
Background variables regarding the inactivity prevalence were assessed during an investigator-patient interview. 
Individual physical activity reports referencing the frequency, duration and type of physical activities were con-
structed following the instructions of the Global Physical Activity  Questionnaire50. A patient was considered to be 
physically inactive if he or she reported less than 3 × 30 min of moderate-intensity physical activity per  week51,52.
The primary outcome measures were collected in both groups before and after the experimental and control 
conditions. The modifiers and background variables were collected only before the start of the experimental or 
control conditions.
Sample size calculation. The study sample size was determined based on the results from previously pub-
lished articles, which reported changes in lower extremity muscle strength in CKD5-HD patients who under-
went intradialytic exercise  intervention53–55. We estimated that to have 80% power to detect an effect size of 0.60 
in a change of a primary outcome between EXG and CON (two-tailed, α level of 0.05) at p < 0.05, 27 patients 
were required in each group. Anticipating a 70% retention rate during the study, we planned to enroll at least 39 
patients in each group.
Statistical analysis. First, we assessed background variables and compared those of the two study groups 
for possible differences using χ2 tests for categorical (binary) variables and the Student´s t-test for continuous 
variables. Second, we assessed whether baseline expression profiles of hsa-miRNA-206 and hsa-miRNA-23a 
modified the relative change in isometric HF force, overall and for the experimental and control conditions 
separately. We did so by using linear regression analyses of the change in the isometric HF by group condition 
(interventional vs. control condition), and whether baseline expression profiles of hsa-miRNA-206 and hsa-
miRNA-23a modified this association. The level of significance was set at an α level of 0.05. Data analyses were 
carried out using the statistical software package IBM SPSS 22.056.
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Data availability
The datasets generated during and/or analysed during the current study are available in the Zenodo repository 
(https ://doi.org/10.5281/zenod o.36782 85).
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